Elekta AB - Nine-month interim report May - January 2006/07

Elekta AB - Nine-month interim report May - January 2006/07

• Order bookings rose 12 percent to SEK 3,539 M (3,162). Order backlog amounted to SEK 4,191 M, a record high level. 
• Net sales increased 1 percent to SEK 3,082 M (3,037).
• Operating profit amounted to SEK 246 M (252) and the operating margin was 8 percent (8). On a rolling 12-month basis, the operating margin was 10 percent.
• Profit after taxes amounted to SEK 183 M (167). Earnings per share after dilution amounted to SEK 1.95 (1.76).
• Cash flow after investments was a negative SEK 324 M (neg. 137). Acquisitions are included in the amount of SEK 144 (192) M.
• In Q4 2006/07, Elekta expects high volumes of deliveries and consequently an operating profit representing over 50 percent of the full year. 
• Operating margin for full year 2006/07 is expected to be 11-12 percent, compared with the previous forecast of 11-14 percent.

For the full report, please see enclosed pdf file. 



For further information, please contact: 

Peter Ejemyr, Group VP Corporate Communications 
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com 

About Elekta 

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.